Castle Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
February 28, 2024 at 04:09 pm EST
Share
Castle Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 219.79 million compared to USD 137.04 million a year ago. Net loss was USD 57.47 million compared to USD 67.14 million a year ago.
Basic loss per share from continuing operations was USD 2.14 compared to USD 2.58 a year ago.
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
CASTLE BIOSCIENCES, INC. 
